Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy

Jeon, Ye Won; Park, Hyung Soon; Ko, Yousun; Sung, Yu Sub; Shim, Byoung Yong; Suh, Young Jin; Kim, Hyun A

doi:10.1007/s10549-021-06322-4

Cited by 7 publications

(2 citation statements)

References 32 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Furthermore, cancer patients who experience severe toxicities have a worse quality of life and physical function overall. Athough other studies reported conflicting results [22][23][24][25][26], sarcopenia resulted to be correlated with higher rates of toxicity [27][28][29][30][31][32], thus we believe that it could indirectly influence the quality of life of cancer patients. The published results in these studies are based on relatively small numbers of patients.…”

Section: Introductionmentioning

confidence: 73%

Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Roberto,

Barchiesi,

Resuli

et al. 2024

Cancers

View full text Add to dashboard Cite

(1) Background: We estimated the prevalence and clinical outcomes of sarcopenia among breast cancer patients. (2) Methods: A systematic literature search was carried out for the period between July 2023 and October 2023. Studies with breast cancer patients evaluated for sarcopenia in relation to overall survival (OS), progression-free survival (PFS), relapse of disease (DFS), pathological complete response (pCR), or toxicity to chemotherapy were included. (3) Results: Out of 359 screened studies, 16 were eligible for meta-analysis, including 6130 patients, of whom 5284 with non-MBC. Sarcopenia was evaluated with the computed tomography (CT) scan skeletal muscle index and, in two studies, with the dual-energy x-ray absorptiometry (DEXA) appendicular lean mass index. Using different classifications and cut-off points, overall, there were 2007 sarcopenic patients (33%), of whom 1901 (95%) presented with non-MBC. Sarcopenia was associated with a 33% and 29% higher risk of mortality and progression/relapse of disease, respectively. Sarcopenic patients were more likely to develop grade 3–4 toxicity (OR 3.58, 95% CI 2.11–6.06, p < 0.0001). In the neoadjuvant setting, a higher rate of pCR was observed among sarcopenic patients (49%) (OR 2.74, 95% CI 0.92–8.22). (4) Conclusions: Our meta-analysis confirms the correlation between sarcopenia and negative outcomes, especially in terms of higher toxicity.

show abstract

Section: Introductionmentioning

confidence: 73%

Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Roberto,

Barchiesi,

Resuli

et al. 2024

Cancers

View full text Add to dashboard Cite

show abstract

“…To date, two cross-sectional studies compared patients with breast cancer to healthy subjects and showed, through magnetic resonance imagery, an increase in thigh IMAT content. In a recent study conducted in patients with breast cancer, it was concluded that IMAT was a significant prognostic factor of survival outcomes, highlighting the importance of IMAT development in patients’ health evolution ( 8 ).…”

Section: Introductionmentioning

confidence: 99%

Development of skeletal muscle atrophy and intermuscular adipose tissue in patients with early breast cancer treated with chemotherapy

Mallard

Hucteau

Bender

et al. 2022

American Journal of Physiology-Cell Physiology

View full text Add to dashboard Cite

Background: Chemotherapy is a common therapy to treat breast cancer patients but also leads to skeletal muscle deconditioning. Skeletal muscle deconditioning is multifactorial and intermuscular adipose tissue (IMAT) accumulation is closely linked to muscle dysfunction. To date, there is no clinical study available investigating IMAT development through a longitudinal protocol and the underlying mechanisms remain unknown. Our study was dedicated to investigating IMAT content in early breast cancer patients treated with chemotherapy and exploring the subsequent cellular mechanisms involved in its development. Methods: We included thirteen women undergoing chemotherapy. Muscle biopsies and ultrasonography assessment were performed before and after chemotherapy completion. Histological and western blotting analyses were conducted. Results: We found a substantial increase in protein levels of three mature adipocyte markers (perilipin, +901%; adiponectin, +135%; FABP4, +321%; p<0.05). These results were supported by an increase in Oil red O-positive staining (+358%; p<0.05). A substantial increase in PDGFRα protein levels was observed (+476%; p<0.05) highlighting an increase in Fibro-adipogenic progenitors (FAPs) content. The cross-sectional area of the vastus lateralis muscle fibers substantially decreased (-21%; p<0.01), and muscle architecture was altered, as shown by a decrease in fascicle length (-15%; p<0.05) and a decreasing trend in muscle thickness -8%; p=0.08). Conclusions: We demonstrated both IMAT development and muscle atrophy in breast cancer patients treated with chemotherapy. FAPs, critical stem cells inducing both IMAT development and skeletal muscle atrophy, also increased, suggesting that FAPs likely play a critical role in the skeletal muscle deconditioning observed in breast cancer patients treated with chemotherapy.

show abstract

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Chan

Vieira

Abar

et al. 2022

Intl Journal of Cancer

View full text Add to dashboard Cite

Previous evidence on postdiagnosis body fatness and mortality after breast cancer was graded as limited-suggestive. To evaluate the evidence on body mass index (BMI), waist circumference, waist-hip-ratio and weight change in relation to breast cancer prognosis, an updated systematic review was conducted. PubMed and Embase were searched for relevant studies published up to 31 October, 2021. Random-effects meta-analyses were conducted to estimate summary relative risks (RRs).The evidence was judged by an independent Expert Panel using pre-defined grading criteria. One randomized controlled trial and 225 observational studies were reviewed (220 publications). There was strong evidence (likelihood of causality: probable) that higher postdiagnosis BMI was associated with increased all-cause mortality (64 studies, 32 507 deaths), breast cancer-specific mortality (39 studies, 14 106 deaths) and second primary breast cancer (11 studies, 5248 events). The respective summary RRs and 95% confidence intervals per 5 kg/m 2 BMI were 1.

show abstract

Intermuscular fat density as a novel prognostic factor in breast cancer patients treated with adjuvant chemotherapy

Cited by 7 publications

References 32 publications

Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Sarcopenia in Breast Cancer Patients: A Systematic Review and Meta-Analysis

Development of skeletal muscle atrophy and intermuscular adipose tissue in patients with early breast cancer treated with chemotherapy

Postdiagnosis body fatness, weight change and breast cancer prognosis: Global Cancer Update Program (CUP global) systematic literature review and meta‐analysis

Contact Info

Product

Resources

About